Navigation Links
Hard To Treat Diseases (HTDS) (H1N1) Vaccine Clinical Approval and Production

SHENZHEN, China, Sept. 14 /PRNewswire-FirstCall/ - HTDS The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary and other general business matters.

At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) Production will be started shortly.

Mr. Terry Yuan CEO of HTDS said (sic) "Mellow Hope has received many inquiries from different countries, asking about the supply of this vaccine. The company is currently in overdrive preparing all the relevant documents to obtain the approval in all of these regions, from various jurisdictional authorities. We are very confident and expect that several significant deals will be finalized by the middle of October, or early November. We remind our shareholders that we beat out a lot of our competitors with our tenders, and we note that some are out in full force planting doubt about our business activities to our novice and unsuspecting shareholders."

Mr. Yuan exclaimed "Our business is doing fantastic! I can't say that any clearer or louder. Our revenues will spike in this 3rd or 4th quarter and once the numbers are released our shareholders will have plenty to smile about. Our audit has commenced, with our aspirations to become an OTCBB Company. I know that our North American office and our representatives there are busy providing the auditors data they require. Few weeks ago when we set the target of our share price of 3 cents per share we did so confidently. Now, with our H1N1 done and completed, HTDS en route to getting its audits completed, OTCBB listed, the cancer and anti aging project's of Slavica Bio Chem, actions we are taking against the naked shorting that has affected our stock, plus the sizable outstanding share reduction; in all fairness a 5 cent target is not an unreasonable or unrealistic target for HTDS."

On that note, Slavica Bio Chem is pleased to provide a video stream of its work. The web stream and English translations are available on under the section "Company News" The video is split in 3 segments. Permission was obtained from RTS TV for non commercial and informative use and to be placed on HTDS website.

Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer summarized as following: "A few years ago Serbian government TV did a feature about our work, and it took a great public attention. It was about Multiple sclerosis, current therapies, there were also some patients, and our whole team. In the video Dr. Sanja Pekovic, Chief Project Scientist and Chief Strategy Officer and Prof Dr. Mirjana Stojiljkovic, Slavica Bio Chme's Medical Advisor can be seen and viewed in the TV documentary. Special thanks go out to Professor Rakic (See Biography Link) ( ). Professor Rakic was pivotal in making Slavica Bio Chem a reality a project that began in 2005 and has expanded to encompass cancer research and anti aging projects.

In other company news, the company through its IR Company retained a former economic crimes prosecutor to investigate trading of its security, and its belief that its security is subject to naked shorting. Mr. Essman is an International business attorney and former Assistant State Attorney of Hillsborough County (Tampa), Florida, where he served with the Special Prosecutions Unit for Economic and White Collar Crimes. His has offices in Tarpon Springs and St. Petersburg, Florida.

The issuer's shareholders and followers can expect updates on these matters shortly as the Company is adamant to get to the bottom of that topic and has instructed its barrister to vigorously pursue the matter.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, please contact

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X Pharmaceuticals Receives Award from NIAID to Develop Antibiotic Treatment for Gonorrhea
2. Study Shows Tubal Reversal Surgery is the Best Treatment to Have More Children After a Tubal Ligation
3. Drug Offers Hope Against Tough-to-Treat Hypertension
4. Hard To Treat Diseases (HTDS) MEVAC-A Completes Tender For Bangladesh
5. New Directions in Angioedema: A Focus on Supportive Care and Treatment Options
6. Most Pharmaceutical Companies Receive Poor Grades on HIV/AIDS Drug Development Innovation, According to AIDS Treatment Activist Coalition Report Card
7. The American Legion Appeals to Congress for Compassionate Treatment of Women Veterans
8. Treating Childhood Leukemia With Fewer Side Effects
9. Hard To Treat Diseases (HTDS) Equipment Purchase, and General Update on its Cancer and Anti Aging Projects
10. Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)
11. Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering Ones Risk of Infection During Treatment
Post Your Comments:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... the 1980s we have seen vast improvements in scientific research and discoveries, leading ... strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s cross-platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... , ... XTC Semifinals 2016 - CES, Las Vegas, Nevada - ... CES 2016, the world’s largest Consumer Electronic Show, where they will present to a ... of Pacific Investments Veronica Serra, and venture capitalist Tim Draper among many other top ...
(Date:12/1/2015)... ... 2015 , ... SonaCare Medical congratulates the University College London ... on November 18th. This prestigious award recognizes annually organizations that cultivate truly innovative ... medical landscape. , The UCLH team won the award for their innovative approach ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology: